Fidelity SPDR Advertisement
Home > Boards > US OTC > Medical - Healthcare >

Itonis Inc. (ITNS)

ITNS RSS Feed
Add ITNS Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator sunspotter, stealofadeal, Pennystock9449, Fishercat, YouOnlyLiveOnce
Search This Board:
Last Post: 10/24/2014 5:23:47 PM - Followers: 386 - Board type: Free - Posts Today: 0

                      

Itonis Holdings



 

OTC Pink Current Information

 

Market Value
$2,470,928  a/o Mar 05, 2014


Shares Outstanding
930,377'519  a/o Aug 31, 2013

Float
551,162,197 a/o May 31, 2013
 

Authorized Shares
1,000,000,000  a/o Aug 31, 2013

http://itonisholdings.com/

and

http://paramountdiscoveries.com/

 

 

 

 

   
1. devision


ABOUT ITONIS PHARMACEUTICALS

Itonis pharmaceuticals was created as a new division of Itonis, Inc. in collaboration with world-famous Dr. Charles Hensley, the inventor of the Zicam® Cold Remedy. This innovative pharmaceutical organization will produce and market prescription homeopathic preparations and over-the-counter products to treat chronic diseases and common ailments. The company will select products based on the speed to market seeking to bypass where appropriate the traditional and lengthy FDA approval process, while still maintaining the strictest levels of both safety and efficacy.

Dr. Hensley is a pioneer in the development and marketing of safe and effective therapeutic nutraceutical and homeopathic preparations. He was a founder of Geltech, LLC, the company that launched the Zicam® Cold Remedy, making the product a household name and forever changing the marketing and product placement paradigm for homeopathic drugs in the United States. Dr. Hensley and his team plan to use the same methodologies to revolutionize the treatment of several other common ailments and other chronic diseases.



PIPELINE

 

In late August of 2012, Itonis pharmaceuticals introduced an over-the-counter, systemically active preparation delivered via a nasal and/or sublingual spray for the alleviation of mild to moderate nausea caused by motion sickness, dizziness, migraine, gastroenteritis, food poisoning, and possibly by chemotherapy, without many of the common side effects associated with current OTC and prescription treatments.

While the actual size of the market for nausea related drugs and preparations is difficult to estimate, it is suggested to be over half a billion dollars annually.
Itonis Pharmaceuticals plans to announce the details of upcoming human clinical studies for the nausea preparation formulation over the coming weeks as it files its provisional patents to protect its intellectual property.
 

http://itonisholdings.com/wp-content/uploads/2013/05/Emesyl2-4.jpg


MANAGEMENT TEAM

  • Charles Hensley, Ph.D

Charles Hensley, Ph.D., the inventor of Zicam® cold remedy is a pioneer in the development and marketing of safe and effective therapeutic nutraceutical and homeopathic cocktails. In 1997, Dr. Hensley founded Geltech, LLC., the company that launched Zicam® and made the product a household name. With the launch of of Zicam® cold remedy, Dr. Hensley and co-workers changed the marketing and product placement paradigm for homeopathic drugs in the United States. Dr. Hensley also developed Zicam® Allergy and the nasal delivery systems used in the Zicam® product line extensions. Dr. Hensley and his partners sold their stake in Geltech to Matrixx initiatives (MTXX).

In 2000, Dr. Hensley was president of Zengen, Inc., a bio-pharmaceutical company, and 2003 founded and served as Chairman and CEO of PRB Pharmaceuticals. He recently co-founded Universal Bio Innovations.

He received his B.S. from the University of Oklahoma and his Ph.D. in Physiology and Biophysics from the University of Southern California. He completed his post-doctoral fellowship in Molecular Cardiology at The University of Southern California in 1993. Subsequently he taught at The University of Southern California School of Pharmacy and medical students at the University of California, Riverside.

  • Mark Cheung

Mr. Cheung has more than 20 years of business law and entrepreneurial experience in the legal fields of business litigation and appeals. He has been a name partner at his Irvine, California law firm that has handled numerous business litigation and intellectual property matters, including a trademark case that ended favorably in the U.S. Supreme Court. Through years of litigation matters, Mr. Cheung has confronted unprecedented business operational disputes and relationship issues, providing industry opportunities to enhance and apply problem-solving skills at all levels.

Since 2001, Mr. Cheung has served on and chaired various not-for-profit boards for several organizations in Orange County, California. He chaired a consumer financial non-profit organization that included 20+ staff, over $2 million in assets and $1.7 million in annual revenues. He has chaired at a community college foundation with over $1.5 million in assets and endowments. Mr. Cheung has also served as a board member to several attorney bar associations, including the chair position for one such association.

Through his decade-long experience of serving and giving back to his community, Mr. Cheung found that such charitable organizations provided him first-hand experience with all aspects of the corporate and business world, including personnel, operations, financial, competition concerns, and reserve investing.

Since 2005, Mr. Cheung has also served as an adjunct professor, teaching upper-class levels at Chapman University School of Law.

Mr. Cheung received his Bachelor of Arts degree in Economics from Brandeis University, and his law degree from Boston College Law School. He has also published scholarly articles in the law.
 


2. devision

VERTEX

Paramount Discoveries





 
 


How Paramount Discoveries Became A Scientific Research Company


Paramount Discoveries, Inc. is a scientific research company originally founded in 1995 by Stuart Robbins. The company is the culmination of more than 16 years of dedicated research to develop a process that can stimulate magnetism in several common natural elements and minerals.
Paramount Discoveries' technologies use an arbitrary wave form generator combined with permanent magnets, and apply a rare frequency for each element or mineral to sustain its "magnetic moment", thus controlling the element or mineral.
The 16 years of research has helped Paramount Discoveries to successfully generate these unique frequencies and overcome the overwhelming scientific odds of finding the correct frequency. Now, Paramount Discoveries continues to challenge the scientific community, researching and developing new technologies that prove the astronomical odds of discovering these frequencies are still possible.

Technology / Working on:



 

 

 

Itonis Pharmaceuticals Received Emesyl Samples for Evaluation

Feb 28, 2014

OTC Disclosure & News Service

-

Itonis Pharmaceuticals Received Emesyl Samples for Evaluation

LAGUNA HILLS, CA--(Marketwired - Feb 28, 2014) - Itonis, Inc. (PINKSHEETS: ITNS) is pleased to announce that it has received and is currently evaluating samples of its Emesyl™ product from its manufacturer. Oasis Health Products, Inc. delivered two versions of the Emesyl™ anti-nausea formula which are currently being evaluating for tolerance.

"The two versions differ in terms of preservative," says Ernesto Barron, Itonis' recently appointed Chief Scientific Officer. "We are looking at using a class of preservative that will not only maintain product stability but also will serve to sooth the nasal passages."

About Itonis Pharmaceuticals
Itonis Pharmaceuticals, a new division of Itonis, Inc., is headed by Charles Hensley, Ph.D. This division's mission is to create and market over-the-counter and prescription homeopathic products that better people's lives. Dr. Hensley is a pioneer in the development and marketing of safe and effective therapeutic nutraceutical and homeopathic preparations. He was a founder of the company that launched the Zicam® Cold Remedy, making the product a household name and forever changing the marketing and product placement paradigm for homeopathic drugs in the United States. Dr. Hensley and his team plan to use the same methodologies to revolutionize the treatment of several other common ailments and other chronic diseases.

About Itonis, Inc.
Itonis, Inc. was incorporated in the state of Nevada on July 5, 2005 under the name of Kenshou, Inc., which later changed to Itonis, Inc. on December 2, 2005. Please visit www.itonisholdings.com.

Safe Harbor:
Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's affiliates that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company's filings with the U.S. Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.

Contact:
Itonis, Inc.
 
 

Charles Hensley, Ph.D., Inventor of Zicam(R) Cold Remedy and Itonis Pharmaceuticals to Use Its Exclusive Manufacturer for Emesyl(TM) Anti-Nausea Swab and Oral Spray Products

Posted on
 
May 3, 2013

LAGUNA HILLS, Calif., May 3, 2013 — Itonis, Inc. (ITNS) and Charles Hensley, Ph.D., the inventor of the Zicam(R) Cold Remedy, and founding member of Itonis Pharmaceuticals, are pleased to announce that the Company’s exclusive manufacturer (Oasis Health Products, Inc.) will produce the Company’s anti-nausea swab and its oral spray products under the Emesyl(TM) brand.

The Company expects to commence the production process with Oasis Health Products for Emesyl(TM) in both the swab and oral spray forms.

Dr. Hensley said, “We are excited that we are working with Oasis to produce the first of our Emesyl(TM) anti-nausea products. We look forward to making Emesyl(TM) available to the general public to treat nausea ailments.”

About Itonis Pharmaceuticals

Itonis Pharmaceuticals, a new division of Itonis, Inc., is headed by Charles Hensley, Ph.D. This division’s mission is to create and market over-the-counter and prescription homeopathic products that better people’s lives. Dr. Hensley is a pioneer in the development and marketing of safe and effective therapeutic nutraceutical and homeopathic preparations. He was a founder of the company that launched the Zicam(R) Cold Remedy, making the product a household name and forever changing the marketing and product placement paradigm for homeopathic drugs in the United States. Dr. Hensley and his team plan to use the same methodologies to revolutionize the treatment of several other common ailments and other chronic diseases.

 

UPDATED IBOX 10/23/2014 BELOW BY FISHERCAT

 

 ITONIS HOLDINGS 


  

    22951 Mill Creek Drive, Suite A-1
     Laguna Hills, California 92653

       Phone: (949)-200-8887
            Email: Office@ItonisHoldings.com  

         WEBSITE: http://itonisholdings.com

      EMESYL.COM   &   EMESYL.NET

       

It's been a long road, our hard work is paying off, and we are confident that Emesyl will be a household name. Sincerely, Itonis, Inc.
               $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$


Press Release:   10/22/2014  To Our Shareholders:

We have had many inquiries about stability testing requirements for Emesyl. We hope the following statement answers these questions and / or clarifies any misunderstandings about the process and requirements:
For the product to have a 2 year expiration date, 90 days are required to complete the stability test. ITNS is well into that 90 day period and we will have a 2 year expiration date for Emesyl that is planned for specific distributors.
It should be noted that stability testing is not mandatory for distribution. The product can be distributed without stability testing. The difference is the product will not have an expiration date, which is also common for many homeopathic products on the market today.
I hope this clears things up.

Sincerely,  Itonis Inc.

Press Release:  10/21/2014  Itonis Pharmaceuticals Announces Emesyl® Website on New Nausea Relief Product

Itonis, Inc. (OTC PINKSHEETS: ITNS) is pleased to announce that it has launched its www.emesyl.com website in preparation for the release of its new Emesyl® homeopathic product for nausea relief, with a new and improved packaging design.
On September 12, 2014, after Itonis received the first batch of Emesyl® from its manufacturer and released a photograph showing the original Emesyl® packaging design, Itonis’ executive team immediately decided to modify the Emesyl® packaging to better convey the product message and to drive marketing and ultimate sales.
“We had an opportunity to interrupt the full completion of Emesyl® to improve the packaging in the long-run for marketing purposes and to achieve sales,” said Mark Cheung, Itonis’ CEO, “so we immediately instituted design changes that can be viewed at www.emesyl.com. While we acknowledge the delay, we believe that the immediate box modification was a necessity that minimized further expenses while gaining an improved packaging design that would better deliver retail marketing advantages.”
The Company is also pleased to share that, with the originally delivered Emesyl®, it has obtained letters of intent with distributors, and is negotiating the final distribution agreements. Please stay tuned for further distribution updates.

EMESYL INAUGURAL PRODUCTION RUN DELIVERED FROM OASIS Posted 08:31:00 09/12/2014 by Admin
Emesyl Inaugural Production Run Delivered From Oasis Picture of the very first box of Emesyl we opened after accepting initial delivery. This is just the beginning........Hooray!

Emesyl Inaugural Production Run Delivered From Oasis on 09/12/14 Posted 08:30:00 09/12/2014 by Admin
This is the very first box of Emesyl we opened after accepting our initial delivery from Oasis Health Products! We are super excited! Stay tuned for more great news to come!

Timeline News:   CLICK HERE FOR ALL NEWS



EXCERPT FROM DR HENSLEY 6/2/2014  The Company will market Emesyl® to national retailers, including drugstore retailers, department stores, cruiselines, and other strategic retail sectors upon receiving its first production batch from Oasis. Plans are in place to aggressively market Emesyl® for a significant share of the worldwide over-the-counter pharmaceutical market revenues. The more than 700 of over-the-counter (OTC) drugs on the market today required a prescription 30 years ago, and the shift to non-prescription OTC medicines has allowed consumers to reduce the number of doctor visits for minor ailments. The worldwide market for OTC drugs could exceed $70 billion by 2015, according to a report by Visiongain, a British research company.                                                              

 

ITONIS PHARMACEUTICALS

Itonis pharmaceuticals was created as a new division of Itonis, Inc. in collaboration with world-famous Dr. Charles Hensley, the inventor of the Zicam(R) Cold Remedy. This innovative pharmaceutical organization will produce and market prescription homeopathic preparations and over-the-counter products to treat chronic diseases and common ailments. The company will select products based on the speed to market seeking to bypass where appropriate the traditional and lengthy FDA approval process, while still maintaining the strictest levels of both safety and efficacy.

Dr. Hensley is a pioneer in the development and marketing of safe and effective therapeutic nutraceutical and homeopathic preparations. He was a founder of Geltech, LLC, the company that launched the Zicam(R) Cold Remedy, making the product a household name and forever changing the marketing and product placement paradigm for homeopathic drugs in the United States. Dr. Hensley and his team plan to use the same methodologies to revolutionize the treatment of several other common ailments and other chronic diseases.

Dr. Hensley commented, "We had wide success upon creating the Zicam? Cold Remedy and I believe that similar preparations can be created to treat many other common ailments. We plan to launch several products into this derivative pharmaceutical category over the coming months. It is exciting to be a part of this new venture and we plan to move expeditiously into the marketing of the formulations that we plan to announce."

Dr. Hensley has joined Itonis as President of its Itonis Pharmaceuticals division that Itonis expects to convert into a new subsidiary. The mission of Itonis Pharmaceuticals is to create science-based products to alleviate symptoms of common ailments and chronic conditions.
 
 
:
Charles Hensley, Ph.D., Inventor of Zicam(R) Cold Remedy, and Itonis Pharmaceuticals Announce First Product IRVINE, CA--(Marketwire - Aug 20, 2012) - Itonis, Inc. (PINKSHEETS: ITNS) and Charles Hensley, Ph.D., the inventor of the Zicam(R) cold remedy, are pleased to announce plans to introduce their first product offering since the creation of Itonis Pharmaceuticals, a division of Itonis. The new division will concentrate on marketing over-the-counter and prescription preparations to treat both common ailments and chronic diseases.

Over the coming weeks, Dr. Hensley and Itonis Pharmaceuticals will outline plans to introduce into the marketplace an over-the-counter, systemically active preparation delivered via a nasal and/or sublingual spray for the alleviation of mild to moderate nausea caused by motion sickness, dizziness, migraine, gastroenteritis, food poisoning, and possibly by chemotherapy, without many of the common side effects associated with current OTC and prescription treatments.

Dr. Hensley commented, "I consult for many corporations in the product development and strategic marketing arena but I am especially excited about leading the Itonis Pharmaceuticals team in bringing this product to market. I believe the time is right to begin introduction of what I believe will be a revolutionary product. There have been relatively few innovations within this product category over the past few years and we believe the market is ripe for a new type of nausea preparation that is available over-the-counter. We believe this new preparation will be both safe and effective for a wide range of nausea related conditions."

While the actual size of the market for nausea related drugs and preparations is difficult to estimate, it is suggested to be over half a billion dollars annually.

Itonis Pharmaceuticals plans to announce the details of upcoming human clinical studies for the nausea preparation formulation over the coming weeks as it files its provisional patents to protect its intellectual property.

Dr. Hensley has joined the Itonis team to lead the Itonis Pharmaceuticals division that Itonis expects to convert into a new subsidiary. The mission of Itonis Pharmaceuticals is to create science-based products to alleviate symptoms of common ailments and chronic conditions. These preparations will be categorized as derivative pharmaceuticals in that while the preparations will be both safe and effective, the path to market is faster than traditional pharmaceutical drugs.
 

Emesyl packaging with UPC Code
CLICK HERE FOR PACKAGE DETAIL
 

Itonis Pharmaceuticals Announces First Emesyl® Manufacturer Production Release Date 
LAGUNA HILLS, CA--(Marketwired - Aug 12, 2014) - Itonis, Inc. (PINKSHEETS: ITNS)
Itonis is very excited to announce that the procurement of raw materials for its first production run of Emesyl® is over 90% complete according to its manufacturer, Oasis Health Products.
The actual manufacturing of the company's Emesyl® product is on schedule to begin August 18, 2014. We are pleased to be able to make these dates available to our shareholders. The completion and release of final product, including Quality Control testing will be September 12, 2014.
"We have been working very closely with Oasis and are pleased that the required lead times to procure packaging and raw product materials have been accurate, ensuring confidence that our timelines are met. We're fully confident of the final product release date of September 12, and heavy focus is now in place on getting solid distribution orders. It won't be long before Emesyl® will be available for retail purchase," said Dr. Charles B. Hensley, the inventor of Emesyl® and the Zicam® Cold Remedy.

We are looking forward to these dates being met and distribution to begin for our flagship product Emesyl®, and will be updating shareholders with more information soon.

Itonis Pharmaceuticals Authorizes Start of Emesyl(R) Inaugural Production Run
LAGUNA HILLS, CA--(Marketwired - Jun 25, 2014) - Itonis, Inc. (PINKSHEETS: ITNS) Itonis is pleased to announce that, with the finalization of its new packaging design and product labeling, it has given the go ahead to Oasis Health Products to produce 16,000 units of its Emesyl® homeopathic product. Itonis has pre-paid necessary funds to Oasis to commence the inaugural production run. The Company is excited that we have finally developed Emesyl® to start production. We are in good hands with Oasis Health Products and we cannot wait for the first Emesyl® that we can proudly market and place on store shelves," says Mark Cheung, the Company's CEO.

Itonis Pharmaceuticals Receives NDC Number From FDA to Enable Production and Marketing of Emesyl(R) Product

LAGUNA HILLS, CA--(Marketwired - Jun 2, 2014) - Itonis, Inc. (PINKSHEETS: ITNS) is pleased to announce that the U.S. Food & Drug Administration (FDA) has published final approval of the Company's National Drug Code (NDC) number (59067-001) for its Emesyl® over-the-counter homeopathic product for nausea relief. In addition, the Company recently received a Notice of Allowance from the U.S. Patent & Trademark Office for its Emesyl® trademark. The NDC number and trademark Notice of Allowance has enabled the Company to enter the final stage of its product packaging design, and the production of Emesyl® will soon begin with its manufacturer, Oasis Health Products. The Company will market Emesyl® to national retailers, including drugstore retailers, department stores, cruiselines, and other strategic retail sectors upon receiving its first production batch from Oasis. Plans are in place to aggressively market Emesyl® for a significant share of the worldwide over-the-counter pharmaceutical market revenues.
"Reaching these significant NDC and trademark milestones required a lot of hard work and patience. We have wasted no time in prompting our manufacturer to finalize all steps for the first production run of Emesyl®, bringing us one step closer to market," said Dr. Charles B. Hensley, the inventor of Emesyl® and the Zicam® Cold Remedy.
The more than 700 of over-the-counter (OTC) drugs on the market today required a prescription
30 years ago, and the shift to non-prescription OTC medicines has allowed consumers to reduce the number of doctor visits for minor ailments. The worldwide market for OTC drugs could exceed $70 billion by 2015, according to a report by Visiongain, a British research company. (http://pharma.about.com/od/Over-the-Counter-Medicine/a/The-Over-the-counter-Drug-Industry.htm)

Itonis Pharmaceuticals Received Emesyl Samples for EvaluationLAGUNA HILLS, CA--(Marketwired - Feb 28, 2014) 
Itonis, Inc. (PINKSHEETS: ITNS) is pleased to announce that it has received and is currently evaluating samples of its Emesyl™ product from its manufacturer. Oasis Health Products, Inc. delivered two versions of the Emesyl™ anti-nausea formula which are currently being evaluating for tolerance.

"The two versions differ in terms of preservative," says Ernesto Barron, Itonis' recently appointed Chief Scientific Officer. "We are looking at using a class of preservative that will not only maintain product stability but also will serve to sooth the nasal passages."

*****************************************************************************************************************************************************************************

MANAGEMENT TEAM
Dr.Charles B. Hensley, PH.D
President of Itonis Holdings


Dr. Charles B. Hensley is the pioneer in the development and use of safe and effective therapeutic cocktails. He is a graduate of the University of Oklahoma and received his Ph.D. in Physiology and Biophysics from the University of Southern California.
In the mid 1990's, Dr. Hensley invented of Zicam(R) cold remedy, one of the top cold remedies in the United States. With the launch of ZICAM, Dr. Hensley and co-workers changed the marketing and product placement paradigm for homeopathic drugs in the United States. Dr. Hensley also developed Zicam(R) Allergy and the nasal delivery systems used in the Zicam(R) product line extensions.
Dr. Hensley was CEO and Chairman of Nasal Therapeutics, Inc., CEO of PRB Pharmaceuticals, president of Zengen, and co-founder of Zicam, LLC (formerly Geltech, LLC).

Mark Cheung CEO / President


Mr. Cheung has more than 20 years of business law and entrepreneurial experience in the legal fields of business litigation and appeals. He has been a name partner at his Irvine, California law firm that has handled numerous business litigation and intellectual property matters, including a trademark case that ended favorably in the U.S. Supreme Court. Through years of litigation matters, Mr. Cheung has confronted unprecedented business operational disputes and relationship issues, providing industry opportunities to enhance and apply problem-solving skills at all levels.
Since 2001, Mr. Cheung has served on and chaired various not-for-profit boards for several organizations in Orange County, California. He chaired a consumer financial non-profit organization that included 20 staff, over $2 million in assets and $1.7 million in annual revenues. He has chaired at a community college foundation with over $1.5 million in assets and endowments. Mr. Cheung has also served as a board member to several attorney bar associations, including the chair position for one such association.
Mr. Cheung received his Bachelor of Arts degree in Economics from Brandeis University, and his law degree from Boston College Law School. He has also published scholarly articles in the law.

Steve Pidliskey Vice President / Secretary


Mr. Pidliskey serves as Vice President and Secretary for Itonis, Inc. He is responsible for the management of all company operations and is a visionary leader with a proven track record in motivating, managing and growing large multi-level teams in support of new products and services.
Prior to joining Itonis, Inc. in 2011, Mr. Pidliskey was a Project Executive for IBM Corporation, retiring after a 32 year career. During his tenure with IBM, he was responsible for worldwide sales and services support with contract revenues exceeding $1B annually. He has extensive experience in leading large complex teams responsible for business operations, strategic planning, change management, business process reengineering, and technical sales support. As an Innovative leader, Mr. Pidliskey is known for building strong teams, integrating strategic business partnerships, and delivering high levels of client satisfaction to customer sets ranging from small and medium size businesses to Fortune 500 companies.
Within his community, Mr. Pidliskey has served as a county board member for more than 20 years to a local county government Citizens Advisory Council. He has held several executive positions on the council, and meets monthly with government and community leaders to assist in the development and perpetuation of crime prevention programs in support of law enforcement services. In addition, Mr. Pidliskey has served for over 10 years as a committee member to a local Boy Scout troop and remains active in leading fund raising activities in support of the Boy Scouts of America.

Donald Jolly, Ph.D.  CFO / Treasurer


Dr. Donald L. Jolly, Ph.D. has more than 20 years experience in the Finance Industry. He has served at both the board and executive levels within the banking community, holding numerous executive positions ranging from the Vice President of Marketing to the President/CEO of several California banks. His wide array of corporate and retail experience include all aspects of banking operations, loans, marketing, personnel, and customer relations. His founding of a California bank provided him valuable experience in managing the early developments of a business.
Dr. Jolly also serves as the Chairman and CEO of the Richard A. Neubauer Research Institute, a 501(c)(3) non-profit organization established to further research, medical improvements, and education in Hyperbarics. He has studied in London, Aberdeen, Scotland and California with internationally renowned doctors, developed research facilities in California, worked in Africa and Romania, and made great strides in research as well as the application of Hyperbaric Oxygen Therapy (HBOT). This pursuit has supplemented his banking career with additional operational and business growth experience. 

Oasis | Contract Manufacturing, Private Label Manufacturer, Homeopathy
Oasis Health Products to Provide Manufacturing Services for Itonis Pharmaceuticals Anti-Nausea ProductsLAGUNA HILLS, Calif., May 2, 2013
Itonis, Inc. (ITNS) and Charles Hensley, Ph.D., the inventor of the Zicam(R) Cold Remedy, and founding member of Itonis Pharmaceuticals, are pleased to announce that the Company has entered into a manufacturing agreement with Oasis Health Products, Inc. to manufacture Emesyl(TM), the company's over-the-counter homeopathic products for the relief of nausea.
Dr. Hensley commented, Oasis Health Products was our first choice as our manufacturer for our homeopathic products and we are extremely pleased that they will be providing us with comprehensive contract manufacturing services for our anti-nausea products. Please visit http://www.oasishp.com for additional information.


 

Security Symbol: ITNS   
OTC PINK
Share Structure

Market Value: $10,513,265 a/o Aug 29, 2014
Shares Outstanding: 930,377,519 a/o Aug 31, 2014
Preferred Shares: 5,000,000
Float: 569,631,717 a/o Aug 31, 2014
Authorized Shares: 1,000,000,000 a/o Aug 31, 2014
Par Value: 0.001
Shareholders of Record: 662 a/o Aug 31, 2014
Number of Beneficial Shareholders: Approx 1
Total number of Shareholders: 662

 

 
 

.



 


 

 


 

 

PostSubject
#26495  Sticky Note Just a reminder, ITNS is not a PR lordofinvest 09/12/14 06:52:50 PM
#22188  Sticky Note "I'm a bit surprised that you haven't linked sunspotter 06/06/14 03:40:48 AM
#27685   unfortunately that is a long way off, there hebroots 10/24/14 05:23:47 PM
#27684   it did fly more just on prospects years hebroots 10/24/14 05:21:46 PM
#27683   Sorting through patient hands!! ITNS YouOnlyLiveOnce 10/24/14 05:09:07 PM
#27682   It will run! And not just because of Dr Badman 10/24/14 02:26:12 PM
#27681   Held down, lol, propped up is more like it. kpisme 10/24/14 01:29:33 PM
#27680   It's too bad ITNS has been kept down vodkadejour 10/24/14 12:16:38 PM
#27678   unfortunately I see that as just a flurry hebroots 10/24/14 08:55:44 AM
#27677   When they "release the hounds" (real distribution news), profiteer11 10/24/14 08:38:43 AM
#27676   So with the announcement of a new Emesyl hebroots 10/24/14 08:11:19 AM
#27675   Sweet. Thanks Fisher for he update and I Moroski 10/23/14 07:41:11 PM
#27674   Havent been around much here but updated the Fishercat 10/23/14 07:08:02 PM
#27673   Only It on is knows when distribution starts ezyE 10/23/14 01:23:39 PM
#27672   we will see how it goes, hebroots 10/23/14 11:25:34 AM
#27671   try reaching Fishercat (mod) on that hebroots 10/23/14 11:21:57 AM
#27670   Sounds like they're genuinely moving toward the goal vodkadejour 10/23/14 11:16:05 AM
#27669   Can a mod change the OTC current info Moroski 10/23/14 10:33:25 AM
#27668   "only" goes with "specific", they could have left hebroots 10/23/14 09:19:55 AM
#27667   Of course-- but using ONLY really changes an Moroski 10/23/14 09:12:35 AM
#27666   It can mean that different markets get different hebroots 10/23/14 09:08:32 AM
#27665   You inserted the word 'only' when explaining specific Moroski 10/23/14 08:58:37 AM
#27664   You may remember this June PR, when they hebroots 10/23/14 08:47:52 AM
#27663   ITNS should be very concerned about stability testing hebroots 10/23/14 08:42:32 AM
#27662   However they are gaining legitimacy by doing it, Moroski 10/23/14 08:42:11 AM
#27661   You are right about the dates and I Moroski 10/23/14 08:40:30 AM
#27660   There is no 90 day clock. It should stockcatman 10/23/14 08:33:58 AM
#27659   OK, just an observation that there seem to hebroots 10/23/14 08:29:35 AM
#27658   I am not sorry about being inaccurate. hebroots 10/23/14 08:20:26 AM
#27657   "For the product to have a 2 year profiteer11 10/23/14 08:08:13 AM
#27656   How come nobody here could explain the stability Moroski 10/23/14 07:56:23 AM
#27655   Hopefully product will be on market In a ezyE 10/23/14 06:04:09 AM
#27654   Of course - stating the obvious. We have Moroski 10/23/14 12:03:07 AM
#27653   Show Revenue and not promises of future dreams kpisme 10/22/14 10:27:36 PM
#27652   Key has been low volume at this level. doiling 10/22/14 09:36:22 PM
#27649   You know I called and left a message Moroski 10/22/14 08:09:20 PM
#27645   Fortunately your information is inaccurate. Dr Badman 10/22/14 07:14:17 PM
#27644   Wow news out in response to stability testing... Gman24 10/22/14 06:02:55 PM
#27643   I'm assuming at this point since the website Drizzle 10/22/14 04:53:24 PM
#27642   I really have not been able to discern hebroots 10/22/14 03:11:56 PM
#27641   Isn't the new package involve the exact same Moroski 10/22/14 02:59:25 PM
#27640   That is what they sent me (I hatched hebroots 10/22/14 02:33:19 PM
#27639   They are just getting started because they just hebroots 10/22/14 02:09:21 PM
#27638   Why do you say the are just beginning porty 10/22/14 02:05:06 PM
#27636   I am not sure how to post a hebroots 10/22/14 02:00:36 PM
#27635   Could we get a screenshot of the email please Speedbucket 10/22/14 01:39:19 PM
#27634   they are just beginning on STABILITY TESTING hebroots 10/22/14 01:16:50 PM
#27633   More delays coming, nowhere near ready for production, hebroots 10/22/14 01:12:45 PM
#27632   SUNSPOTTER, reply from ITNS about STABILITY TESTING....(I bet hebroots 10/22/14 01:08:44 PM
#27631   don't feel so bad, back in that timeframe hebroots 10/22/14 01:00:35 PM
#27630   People don't have any choice but to wait. vodkadejour 10/22/14 12:25:13 PM
#27629   U can't. Have to go to the website. Dr Badman 10/22/14 10:39:00 AM
PostSubject